Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8387MR)

This product GTTS-WQ8387MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8387MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7216MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ11026MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ3881MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ15454MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ9915MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ13035MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ11470MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ14232MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG-6107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW